A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase

Trial Profile

A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2011 Status changed to discontinued.
    • 12 May 2009 Additional lead trial centre (Oregon Health and Science University), investigator(Druker BJ) added as reported by ClinicalTrials.gov.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top